| 001 | 292609 | ||
| 005 | 20250512135114.0 | ||
| 024 | 7 | _ | |a 10.1007/s00259-024-06879-4 |2 doi |
| 024 | 7 | _ | |a pmid:39256215 |2 pmid |
| 024 | 7 | _ | |a 1619-7070 |2 ISSN |
| 024 | 7 | _ | |a 1619-7089 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2024-01835 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Pan, Leyun |0 P:(DE-He78)96ac0342a3ccf9553e3d4c9da9b821b0 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Impact of different parametric Patlak imaging approaches and comparison with a 2-tissue compartment pharmacokinetic model with a long axial field-of-view (LAFOV) PET/CT in oncological patients. |
| 260 | _ | _ | |a Heidelberg [u.a.] |c 2025 |b Springer-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1737103313_4128 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:E060#LA:E060# / 2025 Jan;52(2):623-637 |
| 520 | _ | _ | |a The recently introduced Long-Axial-Field-of-View (LAFOV) PET-CT scanners allow for the first-time whole-body dynamic- and parametric imaging. Primary aim of this study was the comparison of direct and indirect Patlak imaging as well as the comparison of different time frames for Patlak calculation with the LAFOV PET-CT in oncological patients. Secondary aims of the study were lesion detectability and comparison of Patlak analysis with a two-tissue-compartment model (2TCM).50 oncological patients with 346 tumor lesions were enrolled in the study. All patients underwent [18F]FDG PET/CT (skull to upper thigh). Here, the Image-Derived-Input-Function) (IDIF) from the descending aorta was used as the exclusive input function. Four sets of images have been reviewed visually and evaluated quantitatively using the target-to-background (TBR) and contrast-to-noise ratio (CNR): short-time (30 min)-direct (STD) Patlak Ki, short-time (30 min)-indirect (STI) Patlak Ki, long-time (59.25 min)-indirect (LTI) Patlak Ki, and 50-60 min SUV (sumSUV). VOI-based 2TCM was used for the evaluation of tumor lesions and normal tissues and compared with the results of Patlak model.No significant differences were observed between the four approaches regarding the number of tumor lesions. However, we found three discordant results: a true positive liver lesion in all Patlak Ki images, a false positive liver lesion delineated only in LTI Ki which was a hemangioma according to MRI and a true negative example in a patient with an atelectasis next to a lung tumor. STD, STI and LTI Ki images had superior TBR in comparison with sumSUV images (2.9-, 3.3- and 4.3-fold higher respectively). TBR of LTI Ki were significantly higher than STD Ki. VOI-based k3 showed a 21-fold higher TBR than sumSUV. Parameters of different models vary in their differential capability between tumor lesions and normal tissue like Patlak Ki which was better in normal lung and 2TCM k3 which was better in normal liver. 2TCM Ki revealed the highest correlation (r = 0.95) with the LTI Patlak Ki in tumor lesions group and demonstrated the highest correlation with the STD Patlak Ki in all tissues group and normal tissues group (r = 0.93 and r = 0.74 respectively).Dynamic [18F]-FDG with the new LAFOV PET/CT scanner produces Patlak Ki images with better lesion contrast than SUV images, but does not increase the lesion detection rate. The time window used for Patlak imaging plays a more important role than the direct or indirect method. A combination of different models, like Patlak and 2TCM may be helpful in parametric imaging to obtain the best TBR in the whole body in future. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a 2-tissue compartment model |2 Other |
| 650 | _ | 7 | |a Kinetic modelling |2 Other |
| 650 | _ | 7 | |a Long axial field-of-view PET/CT |2 Other |
| 650 | _ | 7 | |a Patlak parametric imaging |2 Other |
| 650 | _ | 7 | |a [18F]FDG PET/CT |2 Other |
| 700 | 1 | _ | |a Sachpekidis, Christos |0 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2 |b 1 |u dkfz |
| 700 | 1 | _ | |a Hassel, Jessica |b 2 |
| 700 | 1 | _ | |a Christopoulos, Petros |b 3 |
| 700 | 1 | _ | |a Dimitrakopoulou-Strauss, Antonia |0 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992 |b 4 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1007/s00259-024-06879-4 |0 PERI:(DE-600)2098375-X |n 2 |p 623-637 |t European journal of nuclear medicine and molecular imaging |v 52 |y 2025 |x 1619-7070 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/292609/files/s00259-024-06879-4.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/292609/files/s00259-024-06879-4.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:292609 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)96ac0342a3ccf9553e3d4c9da9b821b0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)69d2d5247c019c2a2075502dc11bf0b2 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2023-08-23 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2023-08-23 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J NUCL MED MOL I : 2022 |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-23 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-23 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-08-23 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b EUR J NUCL MED MOL I : 2022 |d 2023-08-23 |
| 920 | 2 | _ | |0 I:(DE-He78)E060-20160331 |k E060 |l E060 KKE Nuklearmedizin |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E060-20160331 |k E060 |l E060 KKE Nuklearmedizin |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)E060-20160331 |k E060 |l E060 KKE Nuklearmedizin |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::